Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition.
Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition.
复制标题
DOI：
10.1016/j.canlet.2012.06.008
复制
发表时间：
2013-07-01
期刊：
影响因子：
9.7
通讯作者：
Torchilin, Vladimir P.
中科院分区：
文献类型：
--
作者：
Koshkaryev, Alexander;Piroyan, Aleksandr;Torchilin, Vladimir P.
Bleomycin (BLM) is an example of an anticancer drug that should be delivered into cytosol for its efficient therapeutic action. With this in mind, we developed octaarginine (R8)-modified fusogenic DOPE-liposomes (R8-DOPE-BLM). R8-modification dramatically increased (up to 50-fold) the cell-liposome interaction. R8-DOPE-liposomes were internalized via macropinocytosis and did not end up in the lysosomes. R8-DOPE-BLM led to a significantly stronger cell death and DNA damage in vitro relative to all controls. R8-DOPE-BLM demonstrated a prominent anticancer effect in the BALB/c mice bearing 4T1 tumors. Thus, R8-DOPE-BLM provided efficient intracellular delivery of BLM leading to strong tumor growth inhibition in vivo.
登录
查看更多内容
影响因子：
5.1
作者：
Khalil, I. A.;Kogure, K.;Harashima, H.
通讯作者：
Harashima, H.
DOI：
10.1016/j.bbrc.2010.12.062
发表时间：
2011-01-21
影响因子：
3.1
作者：
Furukawa, Ryo;Yamada, Yuma;Harashima, Hideyoshi
通讯作者：
Harashima, Hideyoshi
影响因子：
2.9
作者：
Torchilin, Vladimir P.
通讯作者：
Torchilin, Vladimir P.
影响因子：
3.7
作者：
CHU, CJ;DIJKSTRA, J;SZOKA, FC
通讯作者：
SZOKA, FC
影响因子：
4.8
作者：
Khalil, IA;Kogure, K;Harashima, H
通讯作者：
Harashima, H